Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.
He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.
Biosimilars, Orphan Drugs Headline Market Trends to Watch in Specialty Drug Pipeline
October 13th 2022New and emerging medications in the specialty drug pipeline were discussed during a keynote address at AMCP Nexus 2022 by Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, with biosimilars, orphan drugs, and cell and gene therapies emerging as key trends to watch.
Advocate Speaks on Diet, Holistic Care in Hidradenitis Suppurativa
October 13th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.
Hepatitis C Morbidity, Mortality Risk Reduced in Homeless Patients Through Supportive Housing
October 13th 2022Patients with hepatitis C virus infection and chronic homelessness who were placed into permanent supportive housing exhibited a significantly reduced risk of hospitalization and liver-related morbidity and mortality.
Assessing Surgical Complications in Management of Hidradenitis Suppurativa
October 10th 2022Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.
AMCP Nexus 2022 to Address Evolving Value-Based Frameworks, Shared Decision-Making
October 10th 2022The annual fall meeting of AMCP Nexus 2022 will feature a keynote from one of the top physician-executives in health care, the specialty pharmaceutical pipeline, and insights for managed care stakeholders in selecting and integrating cost-effective, value-based care frameworks.
Dr Melissa O'Connor on Development of Decision Support Tool For Discharge in Home Health
October 8th 2022Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, addressed gaps in research for home health care and progress toward the development of a discharge decision support tool for clinicians.
Advocate Addresses Unmet Needs in the Management of Hidradenitis Suppurativa
October 7th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed several pressing issues that warrant consideration to improve the care management of HS.
Dr Jason Ezra Hawkes Addresses Immunotherapy Innovation, Uptake Issues in Atopic Dermatitis
October 6th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed recent advancements in immunotherapy for atopic dermatitis and what unmet needs persist to address uptake issues and patient-specific care needs.
Panel Reviews Health Inequities and Opportunities for Innovation Through Population Health Delivery
September 30th 2022A panel discussion at the 70th Annual Roy A. Bowers Pharmaceutical Conference addressed recent care delivery initiatives in New Jersey that aim to address health inequities and other population health concerns.
Dr Melissa O'Connor Reviews Considerations for Discharge in Home Health
September 30th 2022Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, discussed several factors for clinicians to consider in creating plans to discharge adults from skilled home health care.
FDA Committee Issues Positive Vote for RBX2660 in Recurrent Clostridioides difficile Infection
September 28th 2022An FDA advisory committee recently issued a positive vote for Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, for its potential in reducing recurrent Clostridioides difficile infection after antibiotic treatment.
Square-Stepping Exercise Linked With Improved Executive Functioning in Parkinson Disease
September 28th 2022Adherence to 8-week square-stepping exercise training among patients with Parkinson disease was associated with significant improvement of executive functioning, as well as cognitive functioning for those with mild cognitive impairment.
Clostridioides difficile Infection Risk Greater Among Patients Requiring Maintenance Hemodialysis
September 27th 2022Patients requiring maintenance hemodialysis (MHD) had a 4-fold higher risk of Clostridioides difficile infection (CDI), with rates of CDI increasing over time regardless of MHD requirement.
Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis
September 26th 2022Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.
Dr Jason Ezra Hawkes Discusses Clinical Considerations for Biologic Treatment in Atopic Dermatitis
September 24th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.
Examining Biologic-Related Adverse Events in CRS With Nasal Polyps
September 23rd 2022Headaches, injection site reactions, and pharyngitis were the most common adverse events associated with the biologic therapies dupilumab, omalizumab, mepolizumab, and reslizumab in the treatment of chronic rhinosinusitis (CRS) with nasal polyps.
Advocate Discusses Surgical, Therapeutic Management of Hidradenitis Suppurativa
September 23rd 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.
Stakeholders Address Innovative Strategies Driving Cancer Outcomes in New Jersey
September 20th 2022Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A. Bowers Pharmaceutical Conference.